))
Episode 580: How ImmunoPrecise Antibodies ($IPA) Uses AI to Transform Antibody-Based Drug Discovery
Manage episode 479076644 series 3486709
Content provided by Global One Media. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Global One Media or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
What happens when decades of lab expertise meet cutting-edge AI? In this interview, Dr. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), talks about how her team is using advanced science and artificial intelligence to develop safer, faster, and more effective antibody-based medicines.
With over 3,000 antibody discovery programs completed, they are transforming the future of drug discovery—cutting time, costs, and risks in the development process. Discover how decades of hands-on lab experience and innovative AI tools are helping identify the best drug candidates faster than ever before.
Learn more about ImmunoPrecise Antibodies: https://www.ipatherapeutics.com/
Watch the full YouTube interview here: https://youtu.be/mE9mDa7uGTs
And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1
569 episodes
Share
